製品名Atto 488 Conjugation Kit (Fast) - Lightning-Link®
Atto 488 Conjugation Kit / Atto 488 Labeling Kit (ab269896) uses a simple and quick process for Atto 488 labeling / conjugation of antibodies. It can also be used to conjugate other proteins or peptides. Learn about our antibody labeling kits and their advantages.
To conjugate an antibody to Atto 488 using this kit:
- add modifier to antibody and incubate for 15 mins
- add quencher and incubate for 5 mins
The Atto 488 conjugated antibody can be used immediately in WB, ELISA, IHC etc. No further purification is required and 100% of the antibody is recovered for use.
Learn about buffer compatibility below; for incompatible buffers and low antibody concentrations, use our rapid antibody purification and concentration kits. Use the FAQ to learn more about the technology, or about conjugating other proteins and peptides to Atto 488.
Custom size conjugation kits up to 100 mg are available on demand. Please contact us to discuss your requirements.
This product is manufactured by Expedeon, an Abcam company, and was previously called Lightning-Link® Rapid Atto 488 Labeling Kit. 350-0015 is the same as the 1 mg size. 350-0010 is the same as the 3 x 100 ug size. 350-0030 is the same as the 3 x 10 ug size. 350-0005 is the same as the 100 µg size.
Amount and volume of antibody for conjugation to Atto 488
Kit size Recommended
amount of antibody1
amount of antibody
3 x 10 µg 3 x 10 µg 3 x 20 µg 3 x 10 µL 100 µg 100 µg 200 µg 100 µL 3 x 100 µg 3 x 100 µg 3 x 200 µg 3 x 100 µL 1 mg 1 x 1 mg 1 x 2 mg 1 x 1 mL
1 Using the maximum amount of antibody may result in less labeling per antibody.
2 Ideal antibody concentration is 1mg/ml. 0.5 - 1 mg/ml can be used if the maximum antibody volume is not exceeded. Antibodies > 2mg/ml or < 0.5 mg/ml should be diluted /concentrated.
Buffer Requirements for Conjugation
Buffer should be pH 6.5-8.5.
Compatible buffer constituents
If a concentration is shown, then the constituent should be no more than the concentration shown. If several constituents are close to the limit of acceptable concentration, then this can inhibit conjugation.
50mM / 0.6% Tris1 0.1% BSA2 50% glycerol 0.1% sodium azide PBS Potassium phosphate Sodium chloride HEPES Sucrose Sodium citrate EDTA Trehalose
1 Tris buffered saline is almost always ≤ 50 mM / 0.6%
2 BSA can also interfere with the use of the conjugated antibody in tissue staining.
Incompatible buffer constituents
Thiomerosal Proclin Glycine Arginine Glutathione DTT
Only purified antibodies are suitable for use, ie. where other proteins, peptides, or amino acids are not present: antibodies in ascites fluid, serum or hybridoma culture media are incompatible.
保存方法Store at -20°C. Please refer to protocols.
内容 100 µg 1 mg 3 x 10 µg 3 x 100 µg ab274065 - Atto 488 mix (Lyophilized) 1 x 100µg 1 x 1mg 3 x 10µg 3 x 100µg ab273994 - Modifier reagent 1 x 200µl 1 x 200µl 1 x 200µl 1 x 200µl ab273995 - Quencher reagent 1 x 200µl 1 x 200µl 1 x 200µl 1 x 200µl
Olling A et al. used ab269896 as part of examining the role of toxins in the pathogenicity of Clostridium difficile.
They used the kit to conjugate Atto 488 to TcdA1–1874 toxin for use in flow cytometry.
Binding of fluorescent labeled TcdA-PE/Cy5 and TcdA1–1874-Atto488 to HT29 and CHO-C6 cells was investigated by FACS analysis. Right shift of the black curve illustrates toxin binding which was detected through fluorescence emission at 667 nm for TcdA and at 523 nm for TcdA1–1874, respectively. Due to different ratio of fluorophor and toxin, fluorescence intensity of TcdA-PE/Cy5 cannot directly be compared with TcdA1–1874-Atto488.
Zeinolabediny Y et al. used ab269896 as part of examining the toxicity of p17 protein assemblies.
They used the kit to conjugate Atto 488 to p17 protein for use in microscopy.
Representative images of the p17 localisation as overlays of Atto 488-fluorescence and light microscopy in worms.
Scale bar = 50 µm. Worms fed for 2 h vehicle (10 mM PB, pH 7.4) or 4 nM p17-Atto 488.
ab269896 は 3 報の論文で使用されています。
- Veldkamp MW et al. Neurokinin-3 receptor activation selectively prolongs atrial refractoriness by inhibition of a background K+ channel. Nat Commun 9:4357 (2018). PubMed: 30341287
- Lindner K et al. Biological effects of carbon black nanoparticles are changed by surface coating with polycyclic aromatic hydrocarbons. Part Fibre Toxicol 14:8 (2017). PubMed: 28327162
- Zeinolabediny Y et al. HIV-1 matrix protein p17 misfolding forms toxic amyloidogenic assemblies that induce neurocognitive disorders. Sci Rep 7:10313 (2017). PubMed: 28871125